Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03

Satoshi Teramukai(Kyoto University Hospital), Masanori Fukushima(Nagoya Institute of Technology), Masahiro Tsuboi(National Cancer Center Hospital East), Kikuo Nakano(Kure Medical Center), Toshiyuki Kitano(Kyoto University), Tadashi Mio(Kyoto University), Kazuhiko Shibata(Kouseiren Takaoka Hospital), Kaoru Kubota(Nippon Medical School Hospital), Yuka Fujita, Kiyoshi Komuta(Osaka Police Hospital), Kiyoyuki Furuse(The Japan-Multinational Trial Organization), Toshiro Yonei(Okayama Medical Center), Yusuke Kishida(Kyoto University Hospital), Masaaki Kawahara(National Kinki Chuo Hospital for Chest Disease), Koichi Minato
European Journal of Cancer
February 22, 2009
10.1016/j.ejca.2009.01.023
Cited by 342

Related Papers

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.3k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
|The Lancet|2022|1.6k